NASDAQ:VRAY ViewRay (VRAY) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.03▼$0.6552-Week Range N/AVolume108.50 million shsAverage Volume7.51 million shsMarket Capitalization$4.59 millionP/E RatioN/ADividend YieldN/APrice Target$3.18 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ViewRay MarketRank™ ForecastAnalyst RatingHold2.14 Rating ScoreUpside/Downside∞ Upside$3.18 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$519,974 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.82 out of 5 stars 3.1 Analyst's Opinion Consensus RatingViewRay has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.18, ViewRay has a forecasted upside of ∞ from its current price of $0.00.Amount of Analyst CoverageViewRay has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for VRAY. Previous Next 0.0 Dividend Strength Dividend YieldViewRay does not currently pay a dividend.Dividend GrowthViewRay does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreViewRay has received a 75.19% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Radiation therapy machines", "MRI machines", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for ViewRay is -0.88. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 2 people have searched for VRAY on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added ViewRay to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ViewRay insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $519,974.00 in company stock.Percentage Held by InsidersOnly 2.50% of the stock of ViewRay is held by insiders.Percentage Held by Institutions92.97% of the stock of ViewRay is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of ViewRay is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ViewRay is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About ViewRay (NASDAQ:VRAY) StockViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.Read More VRAY Stock News HeadlinesAugust 20, 2023 | ca.finance.yahoo.comViewRay Inc (6L9.BE)July 21, 2023 | seekingalpha.comViewRay stock to be delisted from Nasdaq and moved to OTC ExchangeSeptember 22, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. July 21, 2023 | finance.yahoo.comViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketsJuly 18, 2023 | benzinga.comWhy ViewRay Stock Hit A New 52-Week Low TodayJuly 18, 2023 | finanznachrichten.deViewRay, Inc.: ViewRay Files Voluntary Chapter 11 PetitionsJuly 17, 2023 | msn.comWhy ViewRay (VRAY) Stock Hit A New 52-Week Low TodayJuly 17, 2023 | investorplace.comWhy Is ViewRay (VRAY) Stock Down 69% Today?September 22, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. July 17, 2023 | finance.yahoo.comViewRay® Files Voluntary Chapter 11 PetitionsJuly 7, 2023 | msn.comViewRay: Near-Term Bankruptcy Filing Might Be In The Cards - SellMay 26, 2023 | fool.comViewRay (NASDAQ: VRAY)May 25, 2023 | markets.businessinsider.comViewray (VRAY) Receives a Hold from Stifel NicolausMay 16, 2023 | finance.yahoo.comDo You Believe in the Growth Prospects of ViewRay (VRAY)?May 13, 2023 | msn.comMorgan Stanley Maintains ViewRay (VRAY) Equal-Weight RecommendationMay 12, 2023 | finance.yahoo.comNeed To Know: The Consensus Just Cut Its ViewRay, Inc. (NASDAQ:VRAY) Estimates For 2023May 12, 2023 | finance.yahoo.comViewRay's MRIdian® to be Featured at Leading European Radiation Oncology MeetingMay 11, 2023 | finanznachrichten.deViewRay, Inc.: ViewRay Announces First Quarter 2023 ResultsMay 11, 2023 | markets.businessinsider.comB.Riley Financial downgrades Viewray (VRAY) to a HoldMay 11, 2023 | msn.comB. Riley Securities Downgrades ViewRay (VRAY)May 11, 2023 | msn.comViewRay hits 52-week low after pulling guidanceMay 11, 2023 | markets.businessinsider.comBTIG Remains a Hold on Viewray (VRAY)May 10, 2023 | finance.yahoo.comViewRay Announces First Quarter 2023 ResultsMay 9, 2023 | finance.yahoo.comViewRay Announces Conference Call for First Quarter 2023 Financial Results to be Held After Market on May 10, 2023April 18, 2023 | msn.comJefferies Downgrades Viewray (VRAY)April 17, 2023 | markets.businessinsider.comJefferies downgrades Viewray (VRAY) to a HoldApril 17, 2023 | finance.yahoo.comIt's Down 63% But ViewRay, Inc. (NASDAQ:VRAY) Could Be Riskier Than It LooksSee More Headlines Receive VRAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter. Email Address VRAY Company Calendar Last Earnings2/27/2023Today9/22/2023Next Earnings (Estimated)10/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRAY CUSIPN/A CIK1597313 Webwww.viewray.com Phone(440) 703-3210Fax800-417-3459Employees295Year Founded2004Price Target and Rating Average Stock Price Forecast$3.18 High Stock Price Forecast$8.00 Low Stock Price Forecast$1.00 Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-107,330,000.00 Net Margins-104.30% Pretax Margin-104.30% Return on Equity-120.48% Return on Assets-42.39% Debt Debt-to-Equity RatioN/A Current Ratio1.16 Quick Ratio0.91 Sales & Book Value Annual Sales$105.86 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / BookN/AMiscellaneous Outstanding Shares183,402,000Free Float178,817,000Market Cap$4.59 million OptionableOptionable Beta0.81 Social Links The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Scott William Drake (Age 55)Pres, CEO & Director Comp: $1.8MMr. Robert S. McCormack J.D. (Age 56)Chief Legal Officer Comp: $692.36kDr. James F. Dempsey Ph.D. (Age 52)Founder & Chief Scientific Officer Mr. William P. Burke (Age 54)Exec. VP & CFO Drew HillSr. VP of Operations & Devel.Matt HarrisonDirector of Investor RelationsKaren HackstaffVP of MarketingMr. Robert Michael Fuchs (Age 56)Chief HR Officer Dr. Martin Fuss M.D.Ph.D., Chief Medical OfficerMr. Paul Ziegler Jr. (Age 49)J.D., Exec. VP & Chief Commercial Officer More ExecutivesKey CompetitorsHelius Medical TechnologiesNASDAQ:HSDTENDRA Life SciencesNASDAQ:NDRATivic Health SystemsNASDAQ:TIVCNuwellisNASDAQ:NUWEViewRayNASDAQ:VRAYQView All CompetitorsInsiders & InstitutionsWolverine Trading LLCSold 186,300 shares on 8/23/2023Ownership: 0.000%Citadel Advisors LLCSold 294,200 shares on 8/15/2023Ownership: 0.000%Walleye Trading LLCSold 972,300 shares on 8/15/2023Ownership: 0.000%Parallax Volatility Advisers L.P.Bought 1,009,400 shares on 8/14/2023Ownership: 0.000%Jefferies Financial Group Inc.Sold 81,200 shares on 8/14/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions VRAY Stock - Frequently Asked Questions Should I buy or sell ViewRay stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VRAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRAY, but not buy additional shares or sell existing shares. View VRAY analyst ratings or view top-rated stocks. What is ViewRay's stock price forecast for 2023? 7 Wall Street analysts have issued 1 year price targets for ViewRay's stock. Their VRAY share price forecasts range from $1.00 to $8.00. On average, they anticipate the company's share price to reach $3.18 in the next twelve months. View analysts price targets for VRAY or view top-rated stocks among Wall Street analysts. When is ViewRay's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, October 30th 2023. View our VRAY earnings forecast. How were ViewRay's earnings last quarter? ViewRay, Inc. (NASDAQ:VRAY) posted its earnings results on Monday, February, 27th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The company earned $34.70 million during the quarter, compared to the consensus estimate of $34.65 million. ViewRay had a negative net margin of 104.30% and a negative trailing twelve-month return on equity of 120.48%. The firm's quarterly revenue was up 70.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.16) EPS. What is Scott Drake's approval rating as ViewRay's CEO? 5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ViewRay own? Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB). When did ViewRay IPO? (VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers. What is ViewRay's stock symbol? ViewRay trades on the NASDAQ under the ticker symbol "VRAY." Who are ViewRay's major shareholders? ViewRay's stock is owned by many different retail and institutional investors. Top institutional investors include Hodges Capital Management Inc. (1.42%), Parallax Volatility Advisers L.P. (0.00%), Royce & Associates LP (0.53%), Jefferies Financial Group Inc. (0.00%), Simplex Trading LLC (0.00%) and Allspring Global Investments Holdings LLC (0.05%). Insiders that own company stock include Adam Andrew Podbelski, B Kristine Johnson, Brian K Roberts, Caley Castelein, Farhad Fred Ebrahimi, Influence Ltd Strong, International Ltd Fosun, James F Dempsey, Karen Prange, Paul Ziegler Jr, Sanket Shah, Scott William Drake, Susan C Schnabel and Zachary William Stassen. View institutional ownership trends. How much money does ViewRay make? ViewRay (NASDAQ:VRAY) has a market capitalization of $0.00 and generates $105.86 million in revenue each year. The company earns $-107,330,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. How many employees does ViewRay have? The company employs 295 workers across the globe. Does ViewRay have any subsidiaries? The following companies are subsidiares of ViewRay: Vesuvius Acquisition Corp., ViewRay GmbH, and ViewRay Technologies Inc..Read More How can I contact ViewRay? ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The official website for the company is www.viewray.com. The company can be reached via phone at (440) 703-3210, via email at investors@viewray.com, or via fax at 800-417-3459. This page (NASDAQ:VRAY) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ViewRay, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.